Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Monica B Vela, Marshall H Chin, Monica E Peek
No abstract text is available yet for this article.
July 31, 2021: New England Journal of Medicine
#2
Stephanie S Cabler, David A Rosen
No abstract text is available yet for this article.
July 31, 2021: New England Journal of Medicine
#3
Gil D Rabinovici
No abstract text is available yet for this article.
July 28, 2021: New England Journal of Medicine
#4
LETTER
Billy Dunn, Peter Stein, Robert Temple, Patrizia Cavazzoni
No abstract text is available yet for this article.
July 28, 2021: New England Journal of Medicine
#5
G Caleb Alexander, David S Knopman, Scott S Emerson, Bruce Ovbiagele, Richard J Kryscio, Joel S Perlmutter, Aaron S Kesselheim
No abstract text is available yet for this article.
July 28, 2021: New England Journal of Medicine
#6
Moriah Bergwerk, Tal Gonen, Yaniv Lustig, Sharon Amit, Marc Lipsitch, Carmit Cohen, Michal Mandelboim, Einav Gal Levin, Carmit Rubin, Victoria Indenbaum, Ilana Tal, Malka Zavitan, Neta Zuckerman, Adina Bar-Chaim, Yitshak Kreiss, Gili Regev-Yochay
BACKGROUND: Despite the high efficacy of the BNT162b2 messenger RNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections have been reported, including infections among health care workers. Data are needed to characterize these infections and define correlates of breakthrough and infectivity. METHODS: At the largest medical center in Israel, we identified breakthrough infections by performing extensive evaluations of health care workers who were symptomatic (including mild symptoms) or had known infection exposure...
July 28, 2021: New England Journal of Medicine
#7
Dana Guyer
New England Journal of Medicine, Volume 385, Issue 5, Page 391-393, July 2021.
July 24, 2021: New England Journal of Medicine
#8
Joseph T Kannarkat, Eric T Roberts
New England Journal of Medicine, Volume 385, Issue 5, Page 387-389, July 2021.
July 24, 2021: New England Journal of Medicine
#9
David Avelar Rodriguez, Julia Orkin
New England Journal of Medicine, Volume 385, Issue 5, July 2021.
July 24, 2021: New England Journal of Medicine
#10
Nathaniel P Morris
New England Journal of Medicine, Volume 385, Issue 5, Page 385-387, July 2021.
July 24, 2021: New England Journal of Medicine
#11
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, Eileen Gallagher, Ruth Simmons, Simon Thelwall, Julia Stowe, Elise Tessier, Natalie Groves, Gavin Dabrera, Richard Myers, Colin N J Campbell, Gayatri Amirthalingam, Matt Edmunds, Maria Zambon, Kevin E Brown, Susan Hopkins, Meera Chand, Mary Ramsay
BACKGROUND: The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the globe, including a notable increase in cases in the United Kingdom. The effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines against this variant has been unclear. METHODS: We used a test-negative case-control design to estimate the effectiveness of vaccination against symptomatic disease caused by the delta variant or the predominant strain (B...
July 21, 2021: New England Journal of Medicine
#12
Garth Rapeport, Emma Smith, Anthony Gilbert, Andrew Catchpole, Helen McShane, Christopher Chiu
No abstract text is available yet for this article.
July 21, 2021: New England Journal of Medicine
#13
LETTER
Victoria T Chu, Anna R Yousaf, Karen Chang, Noah G Schwartz, Clinton J McDaniel, Scott H Lee, Christine M Szablewski, Marie Brown, Cherie L Drenzek, Emilio Dirlikov, Dale A Rose, Julie Villanueva, Alicia M Fry, Aron J Hall, Hannah L Kirking, Jacqueline E Tate, Tatiana M Lanzieri, Rebekah J Stewart
No abstract text is available yet for this article.
July 21, 2021: New England Journal of Medicine
#14
LETTER
Frank Struyf, Jerald Sadoff, Macaya Douoguih
No abstract text is available yet for this article.
July 21, 2021: New England Journal of Medicine
#15
EDITORIAL
Stephen J W Evans, Nicholas P Jewell
No abstract text is available yet for this article.
July 21, 2021: New England Journal of Medicine
#16
Peter Verhamme, B Alexander Yi, Annelise Segers, Janeen Salter, Daniel Bloomfield, Harry R Büller, Gary E Raskob, Jeffrey I Weitz
BACKGROUND: The role of factor XI in the pathogenesis of postoperative venous thromboembolism is uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation. METHODS: In this open-label, parallel-group trial, we randomly assigned 412 patients who were undergoing total knee arthroplasty to receive one of three regimens of abelacimab (30 mg, 75 mg, or 150 mg) administered postoperatively in a single intravenous dose or to receive 40 mg of enoxaparin administered subcutaneously once daily...
July 19, 2021: New England Journal of Medicine
#17
Ali M Ayyash, Rahul Sampath
New England Journal of Medicine, Volume 385, Issue 4, July 2021.
July 17, 2021: New England Journal of Medicine
#18
Amy Moran-Thomas
New England Journal of Medicine, Volume 385, Issue 4, Page 293-295, July 2021.
July 17, 2021: New England Journal of Medicine
#19
Lucy E Marcil, Katherine G Barnett, Barry Zuckerman
New England Journal of Medicine, Volume 385, Issue 4, Page 289-291, July 2021.
July 17, 2021: New England Journal of Medicine
#20
Salvatore Mangione, Mark L Tykocinski
New England Journal of Medicine, Volume 385, Issue 4, Page 291-293, July 2021.
July 17, 2021: New England Journal of Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
